04 Feb 2022 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results Member news
25 Jan 2022 Large UK study shows rapid EGFR testing with Idylla™ alongside NGS has potential to enhance lung cancer patient health outcomes Member news
24 Jan 2022 BIMZELX[®] (bimekizumab) approved in Japan for the treatment of plaque psoriasis, generalized pustular psoriasis and psoriatic erythroderma Member news
21 Jan 2022 argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis Member news
20 Dec 2021 argenx announces U.S. Food and Drug Administration (FDA) approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis Member news
16 Nov 2021 New study demonstrates Idylla™ EGFR Mutation Test (CE-IVD) shortens time to patient management decisions for patients with non-small cell lung cancer Member news
15 Nov 2021 Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
